Literature DB >> 17904162

Optimal bacteriophage mutation rates for phage therapy.

David T Kysela1, Paul E Turner.   

Abstract

The mutability of bacteriophages offers a particular advantage in the treatment of bacterial infections not afforded by other antimicrobial therapies. When phage-resistant bacteria emerge, mutation may generate phage capable of exploiting and thus limiting population expansion among these emergent types. However, while mutation potentially generates beneficial variants, it also contributes to a genetic load of deleterious mutations. Here, we model the influence of varying phage mutation rate on the efficacy of phage therapy. All else being equal, phage types with historical mutation rates of approximately 0.1 deleterious mutations per genome per generation offer a reasonable balance between beneficial mutational diversity and deleterious mutational load. We determine that increasing phage inoculum density can undesirably increase the peak density of a mutant bacterial class by limiting the in situ production of mutant phage variants. For phage populations with minimal genetic load, engineering mutation rate increases beyond the mutation-selection balance optimum may provide even greater protection against emergent bacterial types, but only with very weak selective coefficients for de novo deleterious mutations (below approximately 0.01). Increases to the mutation rate beyond the optimal value at mutation-selection balance may therefore prove generally undesirable.

Entities:  

Mesh:

Year:  2007        PMID: 17904162     DOI: 10.1016/j.jtbi.2007.08.007

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  6 in total

1.  Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria.

Authors:  Flavie Pouillot; Hélène Blois; François Iris
Journal:  Biosecur Bioterror       Date:  2010-06

2.  Bacteriophage PBC1 and its endolysin as an antimicrobial agent against Bacillus cereus.

Authors:  Minsuk Kong; Sangryeol Ryu
Journal:  Appl Environ Microbiol       Date:  2015-01-16       Impact factor: 4.792

3.  Decreasing Enterobacter sakazakii (Cronobacter spp.) food contamination level with bacteriophages: prospects and problems.

Authors:  Sophie Zuber; Catherine Boissin-Delaporte; Lise Michot; Carol Iversen; Benjamin Diep; Harald Brüssow; Pieter Breeuwer
Journal:  Microb Biotechnol       Date:  2008-11       Impact factor: 5.813

4.  Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy.

Authors:  Benjamin J Cairns; Andrew R Timms; Vincent A A Jansen; Ian F Connerton; Robert J H Payne
Journal:  PLoS Pathog       Date:  2009-01-02       Impact factor: 6.823

5.  Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1.

Authors:  Alex Betts; Marie Vasse; Oliver Kaltz; Michael E Hochberg
Journal:  Evol Appl       Date:  2013-07-15       Impact factor: 5.183

6.  Encapsulation of Bacteriophage in Liposome Accentuates Its Entry in to Macrophage and Shields It from Neutralizing Antibodies.

Authors:  Saloni Singla; Kusum Harjai; Om Prakash Katare; Sanjay Chhibber
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.